Table S4.
Summarized results from the additional sensitivity analyses in comparison to the base case
| Parameters | Base case | Additional sensitivity analyses | Results (EUR per QALY gained) |
|---|---|---|---|
| Time horizon | 10 years | 1 year | 55,064 |
| 2 years | 33,947 | ||
| 5 years | 30,123 | ||
| Post-progression treatments included | No | Yes | 37,338 |
| Progression-free survival function | Afatinib independent review – loglogistic Erlotinib independent review – loglogistic |
Afatinib independent review – Weibull Erlotinib independent review – Weibull |
24,842 |
| Afatinib independent review – lognormal Erlotinib independent review – lognormal |
29,876 | ||
| Afatinib investigator choice – Weibull Erlotinib investigator choice – Weibull |
25,687 | ||
| Afatinib investigator choice – loglogistic Erlotinib investigator choice – loglogistic |
31,025 | ||
| Afatinib investigator choice – lognormal Erlotinib investigator choice – lognormal |
29,291 | ||
| Overall survival function | Afatinib: Weibull Erlotinib: Weibull |
Afatinib: lognormal Erlotinib: lognormal (extreme scenario) |
20,919 |
| Afatinib: Weibull Erlotinib: lognormal (extreme scenario) |
62,546 | ||
| Health state utility data source | LUX-Lung 83 | NICE Nivolumab guidance | 27,315 |
| Nafees et al27 | 31,609 | ||
| AE consideration method | Considering a distribution of the probability of each AE over the time spent in pre- progression | Considering that the probability of each AE is applied one time at the first cycle of the model for all patients | 29,040 |
Abbreviations: AE, adverse event; NICE, National Institute for Health and Care Excellence; QALY, quality-adjusted life year.